Back to search results

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Abroad (travel likely)RecruitingPHASE2

Conditions

HER2-negative Breast Cancer Patients With Brain Metastases

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope--Duarte, Duarte, California, United States

    Contact: Study coordinator (Dr. Hope S. Rugo) · hrugo@coh.org
    Contact: Principal Investigator (Dr. Hope S. Rugo)

  • Cancer & Blood Research Center, LLC, Los Alamitos, California, United States

    Contact: Study coordinator (Dr. Sassan Farjami) · Sfarjami@cbsclinic.com · 562-340-0606
    Contact: Principal Investigator (Dr. Vu Phan)

  • Univ. of California Los Angeles, Los Angeles, California, United States

    Contact: Study coordinator (Rena Callahan) · rcallahan@mednet.ucla.edu
    Contact: Principal Investigator (Rena Callahan)

  • FOMAT Medical Research (Network), Oxnard, California, United States

    Contact: Study coordinator (Dr. Nawazish Khan) · bd@fomatmedical.com · 833-489-4968
    Contact: Principal Investigator (Dr. Nawazish Khan)

  • Scripps Health, San Diego, California, United States

    Contact: Study coordinator (Dr. Tresa McGranahan) · mcgranahan.tresa@scrippshealth.org
    Contact: Principal Investigator (Dr. Tresa McGranahan)

  • University Of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States

    Contact: Study coordinator (Dr. Elena Shagisultanova) · elena.shagisultanova@cuanschutz.edu
    Contact: Principal Investigator (Dr. Elena Shagisultanova)

  • Biosresearch Partner, Hialeah, Florida, United States

    Contact: Study coordinator (Dr. Luis Rangel) · lrangelmd@bioresearchpartner.com · 833-489-4968
    Contact: Principal Investigator (Dr. Luis Rangel)

  • D&H Cancer Research Center, Margate, Florida, United States

    Contact: Study coordinator (Dr. Emilio Araujo-Mino) · drearaujo@dhnrc.com · 833-489-4968
    Contact: Principal Investigator (Dr. Emilio Araujo-Mino)

  • Augusta University, Augusta, Georgia, United States

    Contact: Study coordinator (Dr. Priyanka Raval) · praval@augusta.edu
    Contact: Principal Investigator (Dr. Priyanka Raval)

  • Robert H. Lurie Comprehensive Cancer Center Northwestern University, Chicago, Illinois, United States

    Contact: Study coordinator (Dr. Regina Stein) · rstein@nm.org
    Contact: Principal Investigator (Dr. Regina Stein)

  • The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, United States

    Contact: Study coordinator (Solmaz Sahebjam) · ssahebj1@jh.edu
    Contact: Principal Investigator (Solmaz Sahebjam)

  • Profound Research LLC, Farmington Hills, Michigan, United States

    Contact: Study coordinator (Dr. Savitha Balaraman) · savitha.balaraman@profoundresearch.io
    Contact: Principal Investigator (Dr. Savitha Balaraman)

  • Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

    Contact: Study coordinator (Dr. Liawaty Ho) · Liawaty.Ho@usoncology.com
    Contact: Principal Investigator (Dr. Liawaty Ho)

  • Stony Brook Cancer Center, Stony Brook, New York, United States

    Contact: Study coordinator (Dr. Lea Baer) · Lea.Baer@stonybrookmedicine.edu
    Contact: Principal Investigator (Dr. Lea Baer)

  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Dr. Nuhad Ibrahim) · nibrahim@mdanderson.org
    Contact: Principal Investigator (Dr. Nuhad Ibrahim)

  • Community Clinical Trials, Kingwood, Texas, United States

    Contact: Study coordinator (Dr. Saleha Sajid) · sajidmd@communityclinicaltrials.com
    Contact: Principal Investigator (Dr. Saleha Sajid)

  • Tranquil Clinical Research, Webster, Texas, United States

    Contact: Study coordinator (Dr. John G. Knecht III) · joknecht29@gmail.com
    Contact: Principal Investigator (Dr. John G. Knecht III)
View source on ClinicalTrials.gov(opens in a new tab)